POLYMED1,749.00

Poly Medicure Ltd.

· Pharma & Health
₹ CrorePeersPFIZERRAINBOWONESOURCEKIMSJUBLPHARMAVIJAYAINDGNGRANULESMcap ₹17,728 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity17.5712.2410.2310.23
Return on Assets13.8910.608.188.18
Return on Capital Employed19.5213.129.789.78
Return on Invested Capital14.7914.699.049.11
Margins
EBITDA Margin26.0427.1223.5923.10
Operating Margin21.3922.1717.4317.43
Incremental Operating Margin25.82-21.13
Pretax Margin24.8426.7922.4920.82
Net Income Margin18.7720.2717.1015.67
Net Income to Common Margin18.7720.2717.1815.77
FCF Margin-0.79-5.02-3.61-3.61
Additional
Effective Tax Rate25.1725.4725.3126.19
Dvd Payout Ratio11.138.9611.05
Sustainable Growth Rate15.6111.149.1010.23
Incremental Operating Margin %25.82-21.135.23
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.